Search research articles
Contact Us
Filters
Showing results (621-630 of 762) with videos related to
Page
of 77
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J Morris, Yohann Loriot, Christopher J Sweeney, et al.
Urology
|
April 15, 2014
Weight gain on androgen deprivation therapy: which patients are at highest risk?
Daniel M Seible, Xiangmei Gu, Andrew S Hyatt, et al.
The Prostate
|
August 22, 2006
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
Rajasubramaniam Shanmugam, Vetrichelvan Jayaprakasan, Yesim Gokmen-Polar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2004
PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
Chong-Xian Pan, Michael S Kinch, Peter A Kiener, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer
Vinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Nature Protocols
|
June 28, 2020
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues
Alba Font-Tello, Nikolas Kesten, Yingtian Xie, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib
Abhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Page
of 77
Search research articles
Search
Showing results (621-630 of 762) with videos related to
Sort By:
Page
of 77
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J Morris, Yohann Loriot, Christopher J Sweeney, et al.
Urology
|
April 15, 2014
Weight gain on androgen deprivation therapy: which patients are at highest risk?
Daniel M Seible, Xiangmei Gu, Andrew S Hyatt, et al.
The Prostate
|
August 22, 2006
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
Rajasubramaniam Shanmugam, Vetrichelvan Jayaprakasan, Yesim Gokmen-Polar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2004
PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
Chong-Xian Pan, Michael S Kinch, Peter A Kiener, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer
Vinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Nature Protocols
|
June 28, 2020
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues
Alba Font-Tello, Nikolas Kesten, Yingtian Xie, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Rana R McKay, Amado J Zurita, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib
Abhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Page
of 77